Meeting
2015 ASCO Annual Meeting
One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
Authors
Rahima Jamal
Hopital Notre-Dame, Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada
Rahima Jamal , Leon Van Kempen , Pamela Thebault , Karl Belanger , Jennifer Elisabeth Friedmann , Jean-Pierre M. Ayoub , Eftihia Cocolakis , Shirin Kazemi , Jeanne Dionne , Caroline Lambert , HB Le , Cecile Grange , Jean-Francois Cailhier , Alan Spatz , Rejean Lapointe , Wilson H. Miller Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01676649
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9062)
DOI
10.1200/jco.2015.33.15_suppl.9062
Abstract #
9062
Poster Bd #
305
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
First Author: Rahima Jamal
Poster
2017 ASCO Annual Meeting
Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600-mutant melanoma.
First Author: Paul B. Chapman
Poster
2014 ASCO Annual Meeting
Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma.
First Author: Evan Hersh
Poster
2014 ASCO Annual Meeting
Droplet digital PCR monitoring of BRAF and NRAS plasma DNA as biomarkers of treatment response in stage IV melanoma.
First Author: David Polsky